image
Healthcare - Drug Manufacturers - General - NASDAQ - UK
$ 67.87
-1.02 %
$ 421 B
Market Cap
29.73
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one AZN stock under the worst case scenario is HIDDEN Compared to the current market price of 67.9 USD, AstraZeneca PLC is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one AZN stock under the base case scenario is HIDDEN Compared to the current market price of 67.9 USD, AstraZeneca PLC is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one AZN stock under the best case scenario is HIDDEN Compared to the current market price of 67.9 USD, AstraZeneca PLC is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart AZN

image
$78.0$78.0$76.0$76.0$74.0$74.0$72.0$72.0$70.0$70.0$68.0$68.0$66.0$66.0$64.0$64.0$62.0$62.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
54.1 B REVENUE
18.03%
10 B OPERATING INCOME
22.09%
8.69 B NET INCOME
25.97%
11.9 B OPERATING CASH FLOW
14.65%
-7.98 B INVESTING CASH FLOW
-96.36%
-4 B FINANCING CASH FLOW
39.15%
14.9 B REVENUE
9.78%
2.04 B OPERATING INCOME
-3.32%
1.67 B NET INCOME
-8.86%
2.91 B OPERATING CASH FLOW
-14.07%
-1.18 B INVESTING CASH FLOW
21.99%
-671 M FINANCING CASH FLOW
83.76%
Balance Sheet AstraZeneca PLC
image
Current Assets 25.8 B
Cash & Short-Term Investments 5.65 B
Receivables 0
Other Current Assets 20.2 B
Non-Current Assets 78.2 B
Long-Term Investments 1.73 B
PP&E 11.6 B
Other Non-Current Assets 64.8 B
5.43 %19.39 %11.20 %62.31 %Total Assets$104.0b
Current Liabilities 27.9 B
Accounts Payable 22.5 B
Short-Term Debt 2.5 B
Other Current Liabilities 2.91 B
Non-Current Liabilities 35.3 B
Long-Term Debt 27.6 B
Other Non-Current Liabilities 7.68 B
35.57 %3.95 %4.60 %43.73 %12.16 %Total Liabilities$63.2b
EFFICIENCY
Earnings Waterfall AstraZeneca PLC
image
Revenue 54.1 B
Cost Of Revenue 10.2 B
Gross Profit 43.9 B
Operating Expenses 33.9 B
Operating Income 10 B
Other Expenses 1.31 B
Net Income 8.69 B
60b60b50b50b40b40b30b30b20b20b10b10b0054b(10b)44b(34b)10b(1b)9bRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
81.12% GROSS MARGIN
81.12%
18.50% OPERATING MARGIN
18.50%
13.01% NET MARGIN
13.01%
17.25% ROE
17.25%
6.76% ROA
6.76%
10.30% ROIC
10.30%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis AstraZeneca PLC
image
8b8b7b7b6b6b5b5b4b4b3b3b2b2b1b1b0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 8.69 B
Depreciation & Amortization 6.69 B
Capital Expenditures -4.59 B
Stock-Based Compensation 0
Change in Working Capital -893 M
Others -3.52 B
Free Cash Flow 7.28 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets AstraZeneca PLC
image
Wall Street analysts predict an average 1-year price target for AZN of $86 , with forecasts ranging from a low of $82 to a high of $89 .
AZN Lowest Price Target Wall Street Target
82 USD 20.82%
AZN Average Price Target Wall Street Target
86 USD 26.71%
AZN Highest Price Target Wall Street Target
89 USD 31.13%
Price
Max Price Target
Min Price Target
Average Price Target
9090858580807575707065656060Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
1.05 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
1.6001.6001.4001.4001.2001.2001.0001.0000.8000.8000.6000.6000.4000.4000.2000.2000.0000.0000.950.950.950.950.950.950.950.9850.9850.9851.050.451.400.451.400.451.400.451.400.451.400.451.400.451.400.4651.450.4651.450.491.481.052015201520162016201720172018201820192019202020202021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 11
6. Ownership
Insider Ownership AstraZeneca PLC
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
AstraZeneca rejoins leading U.S. drug lobby group after two-year absence AstraZeneca has rejoined the main U.S. drug lobby group, roughly two years after leaving it, the Pharmaceutical Research and Manufacturers of America (PhRMA) said on Tuesday. reuters.com - 1 week ago
Eli Lilly, Vertex, AbbVie and More Pharma Stocks to Own as Tariffs Loom Trump's tariff policy is the latest uncertainty to plague the pharmaceutical sector. barrons.com - 1 week ago
AstraZeneca reports best trial results in a decade for metastatic breast cancer treatment AstraZeneca PLC (LSE:AZN) reported notable progress in ongoing trials of patients with metastatic breast cancer using a combination of drugs, Enhertu and pertuzumab. Enhertu, jointly developed by the Anglo-Swedish drug company and Japan's Daiichi Sankyo, is being combined with Roche's pertuzumab in the DESTINY-Breast09 Phase III trials, and showed a statistically significant and clinically meaningful improvement in progression-free survival. proactiveinvestors.co.uk - 1 week ago
Should You Buy, Sell or Hold AstraZeneca Stock Before Q1 Earnings? AZN's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, are expected to have driven the company's top line. zacks.com - 1 week ago
LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts. fxempire.com - 1 week ago
Selling America, Buying Europe - My Picks After years of strong returns, amidst the tariff-induced uncertainty, I am rotating towards European-based equities. US economy is facing mounting pressures, via weakening consumer demand, reduced CAPEX spending, inflation, and rising recession odds. European equities are relatively cheap, and despite structural issues, pockets of opportunities exist in high-growth areas and via re-arming Europe initiative. seekingalpha.com - 1 week ago
European pharma companies issue demands to stay in EU ahead of expected US tariffs Nearly three dozen global pharmaceutical companies, in a letter to the head of the European Commission, demanded help to maintain operations in the EU despite threatened U.S. tariffs on imports, including measures to compensate them for the cost of pharmaceutical innovations, French business newspaper Les Echos reported on Tuesday. reuters.com - 2 weeks ago
Trump Says Pharmaceutical Tariffs Coming in Near Future President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporters Monday in the Oval Office. youtube.com - 2 weeks ago
Trump says US pharma tariffs coming in not-too-distant future U.S. President Donald Trump said on Monday that he expects to impose tariffs on imported pharmaceuticals in the not-too-distant future. reuters.com - 2 weeks ago
The Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and Novartis AbbVie's, Rinvoq and AstraZeneca's and Novartis are included in this Analyst Blog. zacks.com - 2 weeks ago
Nasdaq Bear Market: 3 Unstoppable Stocks You Can Buy With $300 Right Now Over the previous seven trading sessions -- i.e., since President Donald Trump announced his "Liberation Day" tariffs -- Wall Street has experienced some of the wildest volatility since the COVID-19 crash in February-March 2020. fool.com - 2 weeks ago
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told CNBC.  The tariffs could disrupt the complex pharmaceutical supply chain, potentially driving up the prices of drugs in the U.S. and exacerbating shortages of critical medicine. cnbc.com - 3 weeks ago
8. Profile Summary

AstraZeneca PLC AZN

image
COUNTRY UK
INDUSTRY Drug Manufacturers - General
MARKET CAP $ 421 B
Dividend Yield 0.00%
Description AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Contact 1 Francis Crick Avenue, Cambridge, CB2 0AA https://www.astrazeneca.com
IPO Date May 12, 1993
Employees 94300
Officers Mr. David Fredrickson Executive Vice-President of Oncology Haematology Business Unit Ms. Pam P. Cheng EVice President of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board Mr. Pascal Claude Roland Soriot D.V.M., M.B.A. Chief Executive Officer & Executive Director Mr. Jeffrey Pott J.D. CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board Ms. Iskra Reic Executive Vice President of International Dr. Susan Mary Galbraith M.D., Ph.D. Executive Vice President of Oncology Haematology R&D Mr. Andrew P. Barnett Head of Investor Relations Gonzalo Vina Head of Global Media Relations Dr. Aradhana Sarin M.D. Chief Financial Officer & Executive Director Dr. Ruud Dobber Ph.D. Executive Vice-President of BioPharmaceuticals Business Unit